Scholarlink

<p>Osteoporosis is a&#xa0;systemic skeletal disorder that is characterised by low bone mineral density (BMD) and deterioration of bone tissue. Eventually, this leads to disruption of bone microarchitecture, a&#xa0;compromised bone strength and an increase risk of fracture. Antiresorptive therapies are used to increase bone strength and reduce the risk of fracture in individuals with osteoporosis. The most common antiresorptives are bisphosphonates, estrogens, selective estrogen receptor modulators (SERM) and the human monoclonal antibody against RANKL (Denosumab).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antiresorptive Therapie der Osteoporose

  • 期刊论文

  • 发表日期：

    2025年9月15日

查看全文
  • Konstantin Horas,
  • Andreas Kurth

摘要

Osteoporosis is a systemic skeletal disorder that is characterised by low bone mineral density (BMD) and deterioration of bone tissue. Eventually, this leads to disruption of bone microarchitecture, a compromised bone strength and an increase risk of fracture. Antiresorptive therapies are used to increase bone strength and reduce the risk of fracture in individuals with osteoporosis. The most common antiresorptives are bisphosphonates, estrogens, selective estrogen receptor modulators (SERM) and the human monoclonal antibody against RANKL (Denosumab).